Endothelial Dysfunction Is Related to Monocyte Activation in Antiretroviral-Treated People With HIV and HIV-Negative Adults in Kenya.
Africa
HIV
I-FABP
antiretroviral therapy
endothelial activation
inflammation
sCD14
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
19
06
2020
accepted:
10
09
2020
entrez:
23
10
2020
pubmed:
24
10
2020
medline:
24
10
2020
Statut:
epublish
Résumé
Residual monocyte activation may contribute to increased risk for endothelial dysfunction and subsequent atherosclerotic cardiovascular diseases (CVDs) among people with HIV (PWH) on antiretroviral therapy (ART). We examined the relationship between monocyte activation and endothelial activation in PWH in Kenya. Serum levels of markers of endothelial activation (soluble/circulating intercellular [sICAM-1] and vascular [sVCAM-1] cell adhesion molecule-1), intestinal barrier dysfunction (intestinal fatty acid binding protein [I-FABP]), and monocyte activation (soluble CD14 [sCD14]) were measured in 275 PWH on ART and 266 HIV-negative persons. Linear regression was used to evaluate associations, adjusting for demographic and traditional CVD risk factors. Among 541 participants, the median age was 43 years, 50% were female, and most PWH were virally suppressed (97%). sICAM-1 and sVCAM-1 levels were significantly higher in PWH than in HIV-negative participants ( Despite viral suppression, African PWH have evidence of enhanced endothelial activation associated with sCD14, suggesting that monocyte activation plays a role in atherosclerotic plaque development. Future studies are needed to determine mechanistic pathways leading to monocyte activation in this population.
Sections du résumé
BACKGROUND
BACKGROUND
Residual monocyte activation may contribute to increased risk for endothelial dysfunction and subsequent atherosclerotic cardiovascular diseases (CVDs) among people with HIV (PWH) on antiretroviral therapy (ART). We examined the relationship between monocyte activation and endothelial activation in PWH in Kenya.
METHODS
METHODS
Serum levels of markers of endothelial activation (soluble/circulating intercellular [sICAM-1] and vascular [sVCAM-1] cell adhesion molecule-1), intestinal barrier dysfunction (intestinal fatty acid binding protein [I-FABP]), and monocyte activation (soluble CD14 [sCD14]) were measured in 275 PWH on ART and 266 HIV-negative persons. Linear regression was used to evaluate associations, adjusting for demographic and traditional CVD risk factors.
RESULTS
RESULTS
Among 541 participants, the median age was 43 years, 50% were female, and most PWH were virally suppressed (97%). sICAM-1 and sVCAM-1 levels were significantly higher in PWH than in HIV-negative participants (
CONCLUSIONS
CONCLUSIONS
Despite viral suppression, African PWH have evidence of enhanced endothelial activation associated with sCD14, suggesting that monocyte activation plays a role in atherosclerotic plaque development. Future studies are needed to determine mechanistic pathways leading to monocyte activation in this population.
Identifiants
pubmed: 33094120
doi: 10.1093/ofid/ofaa425
pii: ofaa425
pmc: PMC7568437
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofaa425Subventions
Organisme : NIAID NIH HHS
ID : P30 AI027757
Pays : United States
Organisme : FIC NIH HHS
ID : R21 TW010459
Pays : United States
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
Microb Pathog. 2018 Jan;114:264-268
pubmed: 29191707
HIV Med. 2015 Nov;16(10):608-19
pubmed: 26111187
J Infect Dis. 2011 Oct 15;204(8):1227-36
pubmed: 21917896
Clin Chim Acta. 2006 Jun;368(1-2):114-9
pubmed: 16445900
Circulation. 2015 Oct 27;132(17):1667-78
pubmed: 26503749
AIDS Res Hum Retroviruses. 2017 Feb;33(2):181-186
pubmed: 27527002
Circulation. 2018 Sep 11;138(11):1100-1112
pubmed: 29967196
J Am Coll Cardiol. 2000 Aug;36(2):423-6
pubmed: 10933352
J Acquir Immune Defic Syndr. 2012 Aug 1;60(4):351-8
pubmed: 22580566
AIDS Rev. 2012 Oct-Dec;14(4):223-30
pubmed: 23258297
Sci Transl Med. 2019 Apr 3;11(486):
pubmed: 30944164
J Am Heart Assoc. 2012 Apr;1(2):
pubmed: 23130122
Nat Med. 2006 Dec;12(12):1365-71
pubmed: 17115046
Acta Physiol (Oxf). 2017 Jan;219(1):22-96
pubmed: 26706498
Adv Immunol. 2013;119:51-83
pubmed: 23886064
AIDS. 2009 Jun 1;23(9):1059-67
pubmed: 19390417
Cardiovasc J Afr. 2018 May/Jun 23;29(3):155-161
pubmed: 29771268
J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):268-73
pubmed: 19387353
J Infect Dis. 2011 Mar 15;203(6):780-90
pubmed: 21252259
Cardiovasc J Afr. 2015 Mar-Apr;26(2 Suppl 1):S6-10
pubmed: 25962950
J Acquir Immune Defic Syndr. 2013 Dec 15;64(5):425-33
pubmed: 23797689
Medicine (Baltimore). 2020 Jul 2;99(27):e20845
pubmed: 32629671
AIDS. 2019 May 1;33(6):1023-1030
pubmed: 30946156
HIV Med. 2016 Feb;17(2):89-105
pubmed: 26452565
Lancet. 2017 Sep 16;390(10100):1211-1259
pubmed: 28919117
J Infect Dis. 2016 Oct 1;214 Suppl 2:S58-66
pubmed: 27625432
J Infect Dis. 2009 Apr 15;199(8):1177-85
pubmed: 19265479
Open Forum Infect Dis. 2016 Oct 15;3(4):ofw224
pubmed: 28066794
J Acquir Immune Defic Syndr. 2016 Dec 15;73(5):507-513
pubmed: 27509250
Open Forum Infect Dis. 2019 Jun 25;6(11):ofz303
pubmed: 31737735
AIDS. 2013 Jul 17;27(11):1803-13
pubmed: 23807276
Acta Physiol (Oxf). 2009 Jun;196(2):193-222
pubmed: 19220204
J Infect Dis. 2016 Oct 15;214(8):1198-204
pubmed: 27354366
Lancet. 1998 Jan 10;351(9096):88-92
pubmed: 9439492
Trends Microbiol. 2013 Jan;21(1):6-13
pubmed: 23062765
J Infect Dis. 2013 Dec 1;208(11):1737-46
pubmed: 24041790
PLoS One. 2019 Apr 4;14(4):e0214735
pubmed: 30946765
AIDS. 2014 Apr 24;28(7):969-77
pubmed: 24691204
J Virol. 2003 Apr;77(8):4588-96
pubmed: 12663765
PLoS One. 2014 Mar 04;9(3):e90541
pubmed: 24594990
J Infect Dis. 2015 Apr 15;211(8):1219-28
pubmed: 25362192
J Immunol. 2000 Jan 1;164(1):13-7
pubmed: 10604986
Atherosclerosis. 2015 May;240(1):154-60
pubmed: 25795556
Arterioscler Thromb Vasc Biol. 2013 Jan;33(1):158-64
pubmed: 23162014
Atherosclerosis. 2006 Feb;184(2):342-7
pubmed: 15979079
Cardiovasc J Afr. 2011 May-Jun;22(3):134-40
pubmed: 21713302
J Clin Endocrinol Metab. 2007 Jul;92(7):2506-12
pubmed: 17456578
HIV Clin Trials. 2016 Mar;17(2):49-54
pubmed: 26739837
Atherosclerosis. 2013 Jul;229(1):246-52
pubmed: 23711612
AIDS. 2015 Jun 19;29(10):1263-5
pubmed: 26035325
J Infect Dis. 2012 Nov 15;206(10):1558-67
pubmed: 23066162
J Infect Dis. 2016 Feb 1;213(3):370-8
pubmed: 26347573
Neurol Neuroimmunol Neuroinflamm. 2018 Dec 21;6(2):e531
pubmed: 30697583
AIDS. 2009 Mar 13;23(5):589-96
pubmed: 19177019
J Acquir Immune Defic Syndr. 2019 Feb 1;80(2):242-245
pubmed: 30422903
Open Heart. 2019 May 22;6(1):e001046
pubmed: 31218009
AIDS. 2003 Mar 28;17(5):765-8
pubmed: 12646805